Introduction to Who Is Eligible for a Dupixent Cancer Lawsuit

  • Who Is Eligible for a Dupixent Cancer Lawsuit? If you who were prescribed Dupixent and were subsequently diagnosed with T-Cell Lymphoma or experienced other severe Dupixent side effects, call Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation as you may qualify for a Dupixent Cancer Lawsuit and possibly entitled to substantial compensation. (855) 846-6529 or [email protected].
  • Dupixent (dupilumab): Is an injectable biologic medication that is used to treat particular types of inflammatory diseases. The medicine is currently the subject of a growing number of lawsuits alleging it causes or accelerates the development of cutaneous T-cell lymphoma (CTCL), a rare form of cancer. As of November 2025, the litigation is in early stages, with no settlements or jury verdicts yet.
  • Recent studies on Dupixent and Cancer:  Have shown that Dupixent use may increase the risk of certain types of cancers known as Cutaneous T-cell Lymphomas (CTCL), including its subtypes Mycosis fungoides and Sezary syndrome, by as much as 300% or more in people who used the medication.

Who Is Eligible for a Dupixent Cancer Lawsuit

The Allegations and Claims in a Dupixent Cancer Lawsuit

  • Negligent manufacturing and marketing: Some lawsuits claim the companies negligently manufactured, distributed, and marketed the drug despite evidence of a link to CTCL and other cancers.
  • Masking symptoms: Plaintiffs claim the drug’s side effects, such as rashes, can mimic CTCL, causing doctors to miss the early signs of cancer and delaying proper treatment.

Medicine concept: text Side Effect on Black chalkboard on grunge wall background, 3D rendering used in Who Is Eligible for a Dupixent Cancer Lawsuit

The Basis for a Dupixent Cancer Lawsuit

  • Primary Basis Dupixent and Cancer Lawsuits: The central claim in the lawsuits is “failure to warn“. Plaintiffs argue that the manufacturers knew or should have known about the potential link between Dupixent and CTCL based on emerging medical studies and adverse event reports, yet did not update the product’s warning label.
  • Key Points: Critical points supporting the litigation include:
    • FDA Investigation: In March 2025, the U.S. Food and Drug Administration (FDA) identified CTCL as a “potential signal of a serious risk” associated with Dupixent and opened a formal safety investigation. The FDA is currently evaluating whether to require a label change.
    • Masking Symptoms: CTCL often initially appears as skin patches that can be mistaken for eczema. Lawsuits allege that Dupixent’s mechanism of action may “unmask” a pre-existing, undiagnosed lymphoma or accelerate its progression, delaying proper cancer diagnosis and treatment.
    • First Wrongful Death Suit: A wrongful death lawsuit was filed in October 2025 by the family of a Tennessee woman who died from T-cell lymphoma shortly after starting Dupixent treatment, marking a significant development in the litigation.

Patient Reports of Cancer Linked to Dupixent

  • Patient and Healthcare Reports on FAERS: In addition to the clinical research and studies, the U.S. Federal and Drug Administration’s (FDA),  Adverse Event Reporting System (FAERS) included numerous patient reports and reports from healthcare providers linking Dupixent (dupilumab) to cancer, specifically to multiple types of T-cell lymphoma. FAERS is a vital database that regulators and researchers use to recognize potential drug risks requiring further investigation.
  • Reports Confirm Clinical Research: As you will note by visiting FAERS from the button below, the current dashboard shows close to 300 reports of T-cell lymphoma cases among Dupixent patients, which includes confirmed reports of cutaneous T-cell lymphoma (CTCL) and other related and serious conditions. These patient and healthcare reports to the FDA continue to fuel concerns that was addressed in clinical studies, strengthening the need for doctors to closely monitoring patients taking Dupixent.
  • The database shows the following type of cases have been reported by patients taking Dupixent or reported by healthcare providers:
    • Cutaneous T-Cell Lymphoma
    • Adult T-Cell Lymphoma/Leukemia
    • T-Cell Lymphoma (general)
    • CTCL, Stage IV
    • CTCL, Stage III
    • Angioimmunoblastic T-Cell Lymphoma
    • CTCL, Stage I
    • Recurrent T-Cell Lymphoma
    • Lymphoma (unspecified)
    • Anaplastic Large Cell Lymphoma (T- and null-cell types)
    • Unclassifiable T-Cell Lymphoma
  • Volume of Reports:  The vast volume of these reports only provides further evidence that Dupixent may be contributing to serious cancer risks in certain patients.

The word SIDE EFFECTS written on a white notepad on a blue background near a stethoscope, syringe, electronic thermometer and pills. Medical concept used in Who Is Eligible for a Dupixent Cancer Lawsuit

What Symptoms of CTCL Might Be Confused with Eczema?

  • Early Stages: In its early stages, cutaneous T-cell lymphoma (CTCL) is frequently misdiagnosed as eczema because the symptoms are almost identical and visually indistinguishable without a biopsy.
  • Symptoms of CTCL: That are commonly confused with eczema include: 
    • Flat, red, or discolored patches: The initial stage of mycosis fungoides (the most common type of CTCL) involves flat patches on the skin that look like a persistent rash or dry, flaky skin. On darker skin tones, these patches may appear lighter or darker than the surrounding skin.
    • Scaly texture: The patches are often scaly, similar to the dry, scaly skin characteristic of eczema and psoriasis.
    • Intense itching (pruritus): Both conditions can cause significant and sometimes severe itching.
    • Location: CTCL rashes often appear in areas not typically exposed to the sun, such as the lower abdomen, buttocks, and upper thighs, which can also be areas affected by eczema. 

Who Is Eligible for a Dupixent Cancer Lawsuit

Key Warning Signs in Dupixent Users

  • Severe Eczema Patients Be Vigilant: For individuals using Dupixent for severe eczema, the diagnostic challenge is compounded because the drug’s anti-inflammatory action may temporarily mask or alter the appearance of early CTCL symptoms.
  • Be Aware of Warning Signs Early: Warning signs that may differentiate CTCL from typical eczema in Dupixent users include:
    • Failure to respond to treatment: Rashes or lesions that persist, worsen, or spread despite ongoing Dupixent use should raise suspicion of an underlying condition.
    • Progression to plaques and tumors: The development of thicker, raised lesions (plaques) or lumps/nodules (tumors) that can ulcerate is a sign of advancing CTCL not typically seen in standard eczema.
    • Development of systemic symptoms: Advanced CTCL can lead to symptoms not associated with eczema, such as persistently swollen lymph nodes (in the neck, armpits, or groin), unexplained fatigue, or weight loss.
    • Sudden acceleration of symptoms: In some case reports, patients experienced a rapid worsening of skin changes shortly after starting Dupixent, suggesting the drug may accelerate the progression of an undetected lymphoma.
  • Skin Changes and Seeking Immediate Medical Help: If you notice persistent or unusual skin changes while on Dupixent, it is crucial to seek a medical evaluation, including a skin biopsy reviewed by a specialist familiar with cutaneous lymphomas

Current Status of Dupixent and Cancer Lawsuits

  • Individual Lawsuits:Dupixent and cancer lawsuits are in the early stages, with individual lawsuits being filed across the United States.
  • No Class Action or MDL (Yet): There is currently no class action lawsuit or multidistrict litigation (MDL) for Dupixent cases, as the damages are considered too severe and unique to each patient for a single class action. However, consolidation into an MDL is possible as more cases are filed.
  • No Recalls or Settlements: As of November 2025, the FDA has not recalled Dupixent, and no settlements or jury verdicts have been reached.

Medical Concept: Side Effect with syringe on blackboard used in Who Is Eligible for a Dupixent Cancer Lawsuit

Who Can Qualify for a Dupixent Cancer Lawsuit?

  • Eligibility: Individuals who used Dupixent and were later diagnosed with cutaneous T-cell lymphoma (CTCL) or related T-cell lymphomas (such as mycosis fungoides or Sézary syndrome) or other severe Dupixent side effects may be eligible to file a personal injury or wrongful death lawsuit.
  • Contact Dupixent Cancer Lawyer Timothy L. Miles: If you or a loved one developed CTCL after using Dupixent, or suffered other severe Dupixent side effects it is recommended to consult with a personal injury attorney promptly, as state laws impose strict deadlines (statutes of limitations) for filing a claim. If you suffered Dupixent and Cancer call Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation. (855)-846-6529 or [email protected].

Compensation in a Dupixent Cancer Lawsuit

  • Eligible: If you are eligible for a Dupixent Lawsuit, a successful plaintiff is entitled to compensatory damages which would include compensation for things such as:
    • past and future medical expenses;
    • pain and suffering including emotional distress; and
    • lost wages and the reduction in your ability to earn an income.
  • Contact Timothy L. Miles: If your case proceeds to trial it is also possible the court could impose punitive damages, intended to punish the defendant for their actions.  Contact Dupixent Lawyer Timothy L. Miles who can tell you if you are eligible for a Dupixent Cancer Lawsuit and can explain more about the type of damages you are entitled to receive.  (855) 846–6529 or [email protected].

If I Was Diagnosed with Dupixent and Cancer, How Do I Get Started?

  • Get a Free Case Evaluation: If you or a loved on developed Dupixent and Cancer after taking Dupixent, the most important thing to do now is get a free case evaluation from a Dupixent Cancer Lawyer to see if you qualify for a Dupixent Cancer Lawsuit. These are not typical cases any lawyer can litigate. Contact Cancer Lawyer Timothy L. Miles who can tell you if you are eligible for a Dupixent Cancer case and can explain more about what will happen next.  (855) 846–6529 or [email protected].
  • Medical Records Review: The earlier your records are reviewed, the stronger the foundation becomes, especially in cases where the biopsy history is limited or where the initial diagnosis was “eczema” that simply never responded the way it should have. A lawyer experienced in drug litigation can help secure the complete medical file, obtain an independent pathology review if necessary, and establish a clear timeline that courts and juries can follow.
  • Time Is of the Essence: If you have a valid case, then it is vital to preserve your rights under the statute of limitations in your state. These deadlines are different in different states, but it normally starts running from the time of diagnosis or from the point when a reasonable person should have realized the connection between the diagnosis and the drug.  Time is of the essence so give Dupixent Cancer Lawyer Timothy L. Miles a call today.

Contingency Fee Agreements: No Cost to Hire a Lawyer

  • ​​​No Fee:  It does not cost anything to hire a lawyer​ if you are eligible for a Dupixent Cancer Lawsuit. We take all cases on a contingency basis which means we do not get paid unless we win or settle your case.
  • Talk with a Lawyer Free of Charge: A lawyer​ can explain the process of a Dupixent Cancer Lawsuit and answer any questions you may have free of charge. The call is free and so is the fee unless we will or settle your case, so call Dupixent Cancer Lawsuit Timothy L. Miles today to see if you may be entitled to significant compensation.

Who Is Eligible for a Dupixent Cancer Lawsuit

FREQUENTLY ASKED QUESTIONS

Contact Timothy L. Miles Today About a Dupixent Cancer Lawsuit

If you believe you qualify for a Dupixent Cancer Lawsuit, contact Dupixent Cancer Lawyer Timothy L. Miles today for a free case evaluation to see if you are eligible for a Dupixent Cancer Lawsuit and possible entitled to substantial compensation.  855/846-6529 or via e-mail at [email protected].(24/7/365).

Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com

Logo law office timothy l. miles used in Who Is Eligible for a Dupixent Cancer Lawsuit